# Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

> **NCT00668200** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 81 (actual)

## Conditions studied

- Paget's Disease of the Bone
- Hypocalcemia

## Interventions

- **DRUG:** Reclast (ZOL446, zoledronic acid)
- **DIETARY_SUPPLEMENT:** Calcium
- **DIETARY_SUPPLEMENT:** Vitamin D

## Key facts

- **NCT ID:** NCT00668200
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668200, "Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00668200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*